<DOC>
	<DOCNO>NCT00129038</DOCNO>
	<brief_summary>The primary objective study ass whether add modified-release dipyridamole aspirin ( Asasantin Retard ) measurable effect marker platelet function ( example , platelet aggregation ) patient cardiovascular disease know resistant aspirin alone</brief_summary>
	<brief_title>Modified-release Dipyridamole/Aspirin ( 200mg/25mg bd ) Versus Aspirin ( 75mg ) Aspirin-resistant Patients</brief_title>
	<detailed_description />
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Cardiovascular disease ( include history stroke transient ischaemic attack ) Documented evidence resistance aspirin Capable comprehend communicate effectively investigator staff provide informed consent . Willing give inform consent prior participation trial . Any clinically significant condition cardiovascular disease . Clinically significant abnormal baseline haematology , blood chemistry urinalysis finding . Use dipyridamole , clopidogrel , ticlopidine nonsteroidal antiinflammatory agent ( NSAID ) ( include COX2 inhibitor ) two week randomisation trial . Active peptic ulceration history peptic ulcer disease . Known history suspect hypersensitivity dipyridamole , aspirin , NSAID component test drug . History bleed disorder . History cerebral haemorrhage . Resting seat blood pressure less 90/60mmHg . Participation drug clinical trial within sixteen week prior start trial . Any indication current previous abuse alcohol , solvent drug . Asthma . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g . oral contraceptive , intrauterine device surgically sterile ) . Previous participation randomisation phase clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>